+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine

Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine

Cns Drugs 24(11): 929-940

Migraine is a disabling, painful primary headache disorder that is associated with various combinations of neurological, gastrointestinal, autonomic and pain symptoms. Gastrointestinal disturbances associated with migraine, including nausea and vomiting, affect a majority of migraineurs and often result in a delay in taking or avoidance of pharmacological intervention. Gastric stasis and vomiting may lead to delayed or inconsistent absorption of orally administered medications. Many migraineurs awake early in the morning with their attack progressing and already associated with nausea and vomiting. As a result, there is a need for a novel, non-invasive, non-oral delivery system for fast and effective acute treatment of migraine. There are two non-oral delivery systems currently available in the US for the acute treatment of migraine: three nasal sprays and two injectable formulations. Although nasal sprays depend partially on nasal mucosal absorption, a significant amount of drug is swallowed, transits the stomach and is absorbed in the small intestine, which is not as rapid or effective a route of delivery for those migraineurs with gastric stasis. Sumatriptan is rapidly absorbed by subcutaneous injection with or without a needle, but the invasiveness and discomfort of the delivery, the high incidence of adverse events and the high recurrence rate all limit its use for many patients. Iontophoretic delivery of medication is a non-invasive transdermal approach that uses small amounts of electrical current to promote rapid movement of the ionized drug through the skin and into the systemic circulation. This delivery bypasses hepatic first-pass metabolism and also avoids gastric transit delay and slowing of small intestinal absorption associated with gastrointestinal stasis in migraineurs. Two pharmacokinetic studies have demonstrated that iontophoretic transdermal delivery of sumatriptan results in rapid and consistent achievement of therapeutic plasma concentrations. These studies also suggest that, by avoiding patient exposure to a rapid rise in and high plasma concentrations of sumatriptan as seen with injectable sumatriptan, transdermal delivery using iontophoresis may significantly reduce typical triptan-related adverse events. A large, randomized, double-blind, placebo-controlled, multicentre clinical trial showed statistically significant efficacy, good tolerability and virtually no triptan-related adverse events. Iontophoretic delivery of sumatriptan, with a novel transdermal patch device, offers patients a migraine-specific medication that is non-invasive and non-oral. Clinically, transdermal delivery provides rapid and effective relief of migraine while bypassing the gastrointestinal tract, with minimal classic triptan-related adverse effects. This unique approach facilitates the rapid absorption of this migraine-specific triptan, which should improve the chances of consistently achieving a therapeutic plasma concentration of sumatriptan, resulting in effective migraine relief.

(PDF emailed within 0-6 h: $19.90)

Accession: 053879167

Download citation: RISBibTeXText

PMID: 20932065

DOI: 10.2165/11317540-000000000-00000

Related references

Sumatriptan transdermal iontophoretic patch (NP101-Zelrixâ„¢): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatric Disease and Treatment 8: 429-434, 2012

Sumatriptan succinate transdermal delivery systems for the treatment of migraine. Journal of Pharmaceutical Sciences 97(6): 2102-2109, 2007

Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics 7(2): 159-163, 2010

Validation of the revised Patient Perception of Migraine Questionnaire (PPMQ-R): measuring satisfaction with acute migraine treatment in clinical trials. Cephalalgia 28(5): 510-523, 2008

Total Migraine freedom for breath powered intranasal delivery of 22 mg Sumatriptan Powder (Avp-825) Versus 100 mg oral sumatriptan from the compass study of acute treatment of Migraine. Value in Health 18(3): A278-A279, 2015

Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. Journal of Neurology 254(2): 242-249, 2007

Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Current Medical Research and Opinion 20(7): 1125-1135, 2004

Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 30(11): 1336-1345, 2011

Anxiety and depression associated with migraine: influence on migraine subjects' disability and quality of life, and acute migraine management. Pain 118(3): 319-326, 2005

Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Pain Management 4(2): 123-128, 2014

A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 52(9): 1402-1410, 2013

Sumatriptan iontophoretic transdermal system for acute treatment of episodic migraine. Expert Review of Neurotherapeutics 16(6): 615-624, 2017

Delivery systems for acute migraine medications. Canadian Family Physician Medecin de Famille Canadien 47(): 322-329, 2001

Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache 41(9): 854-861, 2001

Acute Confusional Migraine: Distinct Clinical Entity or Spectrum of Migraine Biology?. Brain Sciences 8(2): -, 2018